Akeso's Cadonilimab Combo Shows Promise in NSCLC, Bolsters Immunotherapy Portfolio
Event summary
- Akeso presented updated Phase Ib/II data at ELCC 2026 for cadonilimab in combination with anlotinib and docetaxel.
- The study included patients with advanced NSCLC who progressed after prior PD-(L)1 inhibitor therapy, with a median follow-up of 21.45 months.
- The combination regimen demonstrated a median progression-free survival (PFS) of 7.0 months and a disease control rate (DCR) of 95.2%.
- ctDNA clearance after the first treatment cycle correlated with a median PFS of 9.1 months.
The big picture
Akeso's cadonilimab, already approved as a bispecific antibody, is demonstrating versatility in treating immunotherapy-resistant cancers. This Phase Ib/II data expands its potential beyond initial indications, addressing a significant unmet need in NSCLC. The combination approach highlights a broader trend in oncology towards more complex therapeutic regimens to overcome resistance mechanisms, but also introduces challenges in terms of safety and patient management.
What we're watching
- Regulatory Approval
- The success of this combination therapy hinges on securing regulatory approvals beyond its current indications, particularly given the competitive landscape in NSCLC.
- Commercialization
- Akeso's ability to effectively commercialize this regimen will depend on demonstrating long-term efficacy and managing the complexity of a triple combination therapy.
- Competitive Dynamics
- The emergence of other immunotherapy-resistant NSCLC treatments will dictate whether this combination can establish a sustainable market share and pricing power.
Related topics